The article focuses on financing and underwriting issues related to gene therapy. Topics discussed include challenge of how to encourage appropriate investment for the potentially lifesaving therapy, pricing strategies for commercialization of the gene therapy and future aspects one-time payment policy for gene therapy in the U.S. to develop vaccines for rare diseases.